These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 32673447)
21. Opioid Management in Pregnancy and Postpartum. Brown HL Obstet Gynecol Clin North Am; 2020 Sep; 47(3):421-427. PubMed ID: 32762927 [TBL] [Abstract][Full Text] [Related]
22. Duration of medication for opioid use disorder during pregnancy and postpartum by race/ethnicity: Results from 6 state Medicaid programs. Austin AE; Durrance CP; Ahrens KA; Chen Q; Hammerslag L; McDuffie MJ; Talbert J; Lanier P; Donohue JM; Jarlenski M Drug Alcohol Depend; 2023 Jun; 247():109868. PubMed ID: 37058829 [TBL] [Abstract][Full Text] [Related]
23. Opioid Use Disorder and Overdose in the First Year Postpartum: A Rapid Scoping Review and Implications for Future Research. Frankeberger J; Jarlenski M; Krans EE; Coulter RWS; Mair C Matern Child Health J; 2023 Jul; 27(7):1140-1155. PubMed ID: 36840785 [TBL] [Abstract][Full Text] [Related]
24. Factors associated with buprenorphine versus methadone use in pregnancy. Krans EE; Bogen D; Richardson G; Park SY; Dunn SL; Day N Subst Abus; 2016; 37(4):550-557. PubMed ID: 26914546 [TBL] [Abstract][Full Text] [Related]
25. Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts. Schiff DM; Nielsen T; Terplan M; Hood M; Bernson D; Diop H; Bharel M; Wilens TE; LaRochelle M; Walley AY; Land T Obstet Gynecol; 2018 Aug; 132(2):466-474. PubMed ID: 29995730 [TBL] [Abstract][Full Text] [Related]
26. Number of buprenorphine induction attempts impacts maternal and neonatal outcomes: a multicenter cohort study. Kelly JC; Ayala NK; Holroyd L; Raghuraman N; Carter EB; Williams SA; Mills MM; Friedman H; Zhang F; Townsel C Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100998. PubMed ID: 38236700 [TBL] [Abstract][Full Text] [Related]
27. Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study. Mullins N; Galvin SL; Ramage M; Gannon M; Lorenz K; Sager B; Coulson CC J Addict Med; 2020; 14(3):185-192. PubMed ID: 31567599 [TBL] [Abstract][Full Text] [Related]
28. An Integrated Care Model for Pregnant and Postpartum Individuals Receiving Medication for Opioid Use Disorder. Ellis LP; Parlier-Ahmad AB; Scheikl M; Martin CE J Addict Med; 2023 Mar-Apr 01; 17(2):131-139. PubMed ID: 35972153 [TBL] [Abstract][Full Text] [Related]
29. Medications for opioid use disorder in pregnancy in a state women's prison facility. Knittel AK; Zarnick S; Thorp JM; Amos E; Jones HE Drug Alcohol Depend; 2020 Sep; 214():108159. PubMed ID: 32683223 [TBL] [Abstract][Full Text] [Related]
30. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)". Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577 [TBL] [Abstract][Full Text] [Related]
31. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy. Bastian JR; Chen H; Zhang H; Rothenberger S; Tarter R; English D; Venkataramanan R; Caritis SN Am J Obstet Gynecol; 2017 Jan; 216(1):64.e1-64.e7. PubMed ID: 27687214 [TBL] [Abstract][Full Text] [Related]
32. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects. Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302 [TBL] [Abstract][Full Text] [Related]
34. High-Dose Buprenorphine Initiation in the Management of Opioid Use Disorder in Pregnancy. Berry M; Kiefer MK; Hinely KA; Bowden H; Jordan A; Vilensky M; Rood KM Obstet Gynecol; 2024 Jun; 143(6):815-818. PubMed ID: 38574367 [TBL] [Abstract][Full Text] [Related]
36. Outcomes associated with the use of medications for opioid use disorder during pregnancy. Krans EE; Kim JY; Chen Q; Rothenberger SD; James AE; Kelley D; Jarlenski MP Addiction; 2021 Dec; 116(12):3504-3514. PubMed ID: 34033170 [TBL] [Abstract][Full Text] [Related]
37. Mobile, Community-Based Buprenorphine Treatment for Veterans Experiencing Homelessness With Opioid Use Disorder: A Pilot, Feasibility Study. Iheanacho T; Payne K; Tsai J Am J Addict; 2020 Nov; 29(6):485-491. PubMed ID: 32367557 [TBL] [Abstract][Full Text] [Related]
38. The MATernaL and Infant NetworK to Understand Outcomes Associated with Treatment of Opioid Use Disorder During Pregnancy (MAT-LINK): Surveillance Opportunity. Tran EL; Kim SY; England LJ; Green C; Dang EP; Broussard CS; Fehrenbach N; Hudson A; Yowe-Conley T; Gilboa SM; Meaney-Delman D J Womens Health (Larchmt); 2020 Dec; 29(12):1491-1499. PubMed ID: 33227221 [TBL] [Abstract][Full Text] [Related]
39. Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women. Cleary EM; Byron RK; Hinely KA; Talley AW; Costantine MM; Rood KM Obstet Gynecol; 2020 Nov; 136(5):902-903. PubMed ID: 33030872 [No Abstract] [Full Text] [Related]
40. A retrospective analysis of treatment and retention outcomes of pregnant and/or parenting women with opioid use disorder. Lopian KM; Chebolu E; Kulak JA; Kahn LS; Blondell RD J Subst Abuse Treat; 2019 Feb; 97():1-6. PubMed ID: 30577894 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]